A full list of this provider’s research publications can be found on their research profile or PubMed.

• Moudgil A, Rodich G, Jordan SC, Kamil ES: Nephrocalcinosis and renal cysts associated with apparent mineralocorticoid excess syndrome. Pediatr. Nephrol., 15(1-2): 60-2, 2000
• Kamil ES: Recent advances in the understanding and management of primary vesicoureteral reflux and reflux nephropathy. Curr. Opin. Nephrol. Hypertens., 9(2): 139-42, 2000
• Gradman WS, Lerner G, Mentser M, Rodriguez H, Kamil ES: Experience with autogenous arteriovenous access for hemodialysis in children and adolescents. Annals of vascular surgery, 19(5): 609-12, 2005
• Couloures K, Pepkowitz SH, Goldfinger D, Kamil ES, Puliyanda DP: Preventing recurrence of focal segmental glomerulosclerosis following renal transplantation: a case report. Pediatric transplantation, 10(8): 962-5, 2006
• Chand DH, Valentini RP, Kamil ES: Hemodialysis vascular access options in pediatrics: considerations for patients and practitioners. Pediatr. Nephrol., , 2008
• Bhalla V, Nast CC, Stollenwerk N, Tran S, Barba L, Kamil ES, Danovitch G, Adler SG: Recurrent and de novo diabetic nephropathy in renal allografts. Transplantation, 75(1): 66-71, 2003
• Hailey E. Desmond, MS; Clare Lindner, MD; Jonathan P. Troost, PhDet al. Association between psychiatric disorders and glomerular disease. Glomerular Diseases, April, 2021.
• Barisoni L, Barratt J, Campbell K et al. Innovating and invigorating the clinical trial infrastructure for glomerular diseases. Kidney Int (2021) 99:519-523.
• Weaver DJ, Waldo A, Oh G, Kamil ES et al. Time to initiation of anti-hypertensive therapy after onset of elevated blood pressure in patients with primary proteinuric disease. Kidney Medicine 2020, March-April; 2(2):131-138.
• Oh GJ, Waldo A, Paez-Cruz F et al. Steroid-associated side effects in patients with primary proteinuric kidney disease. Kidney International Reports 2019 Sep 9;4(11):1608-1616
• Steggerda JA, Kim IK, Haas M et al: Clinical and Histopathologic Features of Antibody-Mediated Rejection among pediatric renal transplant recipients with preformed vs de novo donor-specific antibodies. Pediatr Transplant. 2017 Dec;21(8).
• Gipson DS, Selewski DT, Massengill SF et al. NephCure Acclerating Cures Institute (NACI): a Multi-Disciplinary Consortium to Improve Care for Nephrotic Syndrome. KI Reports. 3(2):439-446, 2018
• Troost JP, Trachtman H, Nachman PH, et al: An outcomes-based definition of proteinuria remission in Focal Segmental Glomerulosclerosis. Clin J Am Soc Nephrol. 2017 Nov 22
• Kim IK, Choi J, Vo A, et al. Risk factors for the development of antibody-mediated rejection in highly sensitized pediatric kidney transplant recipients. Pediatr Transplant 2017; Dec;21(8).
• Kim IK, Choi J, Vo A, et al. Safety and Efficacy of Alemtuzumab Induction in Highly Sensitized Pediatric Transplant Recipients. Transplantation 101 (4):883-889, 2017.
• Wongsaengsak S, Vidmar AP, Addala A, Kamil ES et al: A New Polymorphic Form of SLC12A1 Gene Mutation Associated with Hyperparathyroidism, Hypercalcemia, Nephrogenic Diabetes Insipidus, and Nephrocalcinosis in Four Patients. Bone. 97:121-125, 2017.
• Chaudhuri A, Ozawa M, Everly MJ, et al. The Clinical Impact of Humoral Immunity in Pediatric Renal Transplantation. J Am Soc Nephrol 24:655-664, 2013.
• Li L, Khatri P, Sigdel TK, Tran TQ, et al: A Peripheral Blood Diagnostic Test for Acute Rejection in Renal Transplantation. Am J Transplant 12(10): 2710—18, 2012. [PMID:23009139]
• Sarwal MM, Benfield M, Ettenger R, et al: Complete steroid avoidance is effective and safe in children with renal transplants: a prospective multicenter randomized controlled trial with 3 year follow up. Am J Transplant 12:2719-29, 2012